France's AB Science watched its shares tank as much as 31% on Friday after a European Medicines Agency panel rejected its gastrointestinal cancer treatment, casting serious doubts on the drug's potential approval. The Committee for Medicinal Products for Human Use (CHMP) ruled against masitinib, a treatment currently used on dogs, and AB Science is appealing the decision, hoping to address the panel's concerns and get a second vote next year. Article